Ampersand’s AMP-220: A Smarter Bet on Precision Cy...
Category : Clinical Trial Update 21 April 2026Cytokines are powerful. They’re also messy. The challenge has never been whether they work&mda...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
Argo Biopharma Advances RNAi Pipeline with Phase I...
Category : Clinical Trial Update 21 April 2026In RNAi therapeutics, progress is measured in durability and precision—not just novelty. Argo...
Ayurveda Meets AI: JSL–Sat Kartar Life Bet on Inte...
Category : Licensing/Collaboration Deal 21 April 2026Ayurveda has scale. Digital health has reach. The problem? They rarely work together. That may be ch...
Beyond Headaches: New INFUSE Study Data Highlights...
Category : Clinical Trial Update 20 April 2026Migraine is not just a headache. It’s a full-body, brain-disrupting condition that affects how...
Nektar Therapeutics to Unveil 52-Week Data from RE...
Category : Clinical Trial Update 20 April 2026Clinical-stage biotech Nektar Therapeutics is gearing up for a key data reveal. On April 20, 2026, t...
Latest Newsletter Post
-
Ayurveda Meets AI: JSL–Sat Kartar L..
21 April 2026
-
Argo Biopharma Advances RNAi Pipeli..
21 April 2026
-
Ampersand’s AMP-220: A Smarter Bet..
21 April 2026
-
Nektar Therapeutics to Unveil 52-We..
20 April 2026
-
Beyond Headaches: New INFUSE Study..
20 April 2026
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com